内科理论与实践

内科理论与实践 >

2021 , Vol. 16 >Issue 03: 145 - 150

DOI: https://doi.org/10.16138/j.1673-6087.2021.03.002

专家论坛

慢性完全闭塞病变介入治疗临床研究进展

展开
  • 复旦大学附属中山医院心内科 上海市心血管病研究所 国家放射与治疗临床医学研究中心,上海 200032

收稿日期: 2021-04-13

  网络出版日期: 2022-07-26

收起

本文引用格式

陆浩, 葛雷 . 慢性完全闭塞病变介入治疗临床研究进展[J]. 内科理论与实践, 2021 , 16(03) : 145 -150 . DOI: 10.16138/j.1673-6087.2021.03.002

参考文献

[1] Luo C, Huang M, Li J, et al. Predictors of interventional success of antegrade PCI for CTO[J]. JACC Cardiovasc Imaging, 2015, 8(7): 804-813.
[2] Grantham JA, Marso SP, Spertus J, et al. Chronic total occlusion angioplasty in the United States[J]. JACC Cardiovasc Interv, 2009, 2(6): 479-786.
[3] Christofferson RD, Lehmann KG, Martin GV, et al. Effect of chronic total coronary occlusion on treatment strategy[J]. Am J Cardiol, 2005, 95(9): 1088-1091.
[4] Kandzari DE, Kini AS, Karmpaliotis D, et al. Safety and effectiveness of everolimus-eluting stents in chronic total coronary occlusion revascularization[J]. JACC Cardiovasc Interv, 2015, 8(6): 761-769.
[5] Ge JB, Ge L, Zhang B, et al. Active greeting technique: a mother-and-child catheter based technique to facilitate retrograde wire externalization in recanalization of coronary chronic total occlusion[J]. Sci Bull, 2018, 63: 1565-1569.
[6] Brilakis ES, Grantham JA, Rinfret S, et al. A percutaneous treatment algorithm for crossing coronary chronic total occlusions[J]. JACC Cardiovasc Interv, 2012, 5(4): 367-379.
[7] Harding SA, Wu EB, Lo S, et al. A new algorithm for crossing chronic total occlusions from the Asia Pacific Chronic Total Occlusion Club[J]. JACC Cardiovasc Interv, 2017, 10(21): 2135-2143.
[8] 中国冠状动脉慢性闭塞病变介入治疗俱乐部. 中国冠状动脉慢性完全闭塞病变介入治疗推荐路径[J]. 中国介入心脏病学杂志, 2018, 26(3): 121-124.
[9] Christopoulos G, Karmpaliotis D, Alaswad K, et al. Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry[J]. Int J Cardiol, 2015, 198: 222-228.
[10] Claessen BE, Dangas GD, Weisz G, et al. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial[J]. Eur Heart J, 2012, 33(6): 768-775.
[11] O’Connor SA, Garot P, Sanguineti F, et al. Meta-analysis of the impact on mortality of noninfarct-related artery coronary chronic total occlusion in patients presenting with ST-segment elevation myocardial infarction[J]. Am J Cardiol, 2015, 116(1): 8-14.
[12] Bataille Y, Déry JP, Larose é, et al. Deadly association of cardiogenic shock and chronic total occlusion in acute ST-elevation myocardial infarction[J]. Am Heart J, 2012, 164(4): 509-515.
[13] Henriques JP, Hoebers LP, Råmunddal T, et al. Percutaneous intervention for concurrent chronic total occlusions in patients with STEMI: the EXPLORE trial[J]. J Am Coll Cardiol, 2016, 68(15): 1622-1632.
[14] Tong J, Yu Q, Li C, et al. Successful revascularization of noninfarct related artery with chronic total occlusion among acute myocardial infarction patients: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2018, 97(3): e9655.
[15] Christakopoulos GE, Christopoulos G, Carlino M, et al. Meta-analysis of clinical outcomes of patients who underwent percutaneous coronary interventions for chronic total occlusions[J]. Am J Cardiol, 2015, 115(10): 1367-1375.
[16] Lee SW, Lee PH, Ahn JM, et al. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion[J]. Circulation, 2019, 139(14): 1674-1683.
[17] Werner GS, Martin-Yuste V, Hildick-Smith D, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions[J]. Eur Heart J, 2018, 39(26): 2484-2493.
[18] Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA(Efficacy of Ranolazine in Chronic Angina) trial[J]. J Am Coll Cardiol, 2006, 48(3): 566-575.
[19] Sapontis J, Salisbury AC, Yeh RW, et al. Early procedural and health status outcomes after chronic total occlusion angioplasty[J]. JACC Cardiovasc Interv, 2017, 10(15): 1523-1534.
[20] Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation(COURAGE) trial nuclear substudy[J]. Circulation, 2008, 117(10): 1283-1291.
[21] Sachdeva R, Agrawal M, Flynn SE, et al. The myocardium supplied by a chronic total occlusion is a persistently ischemic zone[J]. Catheter Cardiovasc Interv, 2014, 83(1): 9-16.
[22] Bucciarelli-Ducci C, Auger D, Di Mario C, et al. CMR guidance for recanalization of coronary chronic total occlusion[J]. JACC Cardiovasc Imaging, 2016, 9(5):547-556.
[23] Jang WJ, Yang JH, Choi SH, et al. Long-term survival benefit of revascularization compared with medical therapy in patients with coronary chronic total occlusion and well-developed collateral circulation[J]. JACC Cardiovasc Interv, 2015, 8(2): 271-279.
[24] Aboul-Enein F, Kar S, Hayes SW, et al. Influence of angiographic collateral circulation on myocardial perfusion in patients with chronic total occlusion of a single coronary artery and no prior myocardial infarction[J]. J Nucl Med, 2014, 45(6): 950-955.
[25] Dong W, Li J, Mi H, et al. Relationship between collateral circulation and myocardial viability of 18F-FDG PET/CT subtended by chronic total occluded coronary arteries[J]. Ann Nucl Med, 2018, 32(3):197-205.
[26] Choi JH, Chang SA, Choi JO, et al. Frequency of myocardial infarction and its relationship to angiographic collateral flow in territories supplied by chronically occluded coronary arteries[J]. Circulation, 2013, 127(6): 703-709.
[27] Małek ŁA, Śpiewak M, Kłopotowski M, et al. Combined analysis of myocardial function, viability, and stress perfusion in patients with chronic total occlusion in relation to collateral flow[J]. Kardiol Pol, 2015, 73(10): 909-915.
[28] Shokry KA, Farag EM, Salem AMH, et al. Relationship between quality of coronary collateral and myocardial viability in chronic total occlusion: a magnetic resonance 1.study[J]. Int J Cardiovasc Imaging, 2021, 37(2): 623-631.
[29] Schumacher SP, Everaars H, Stuijfzand WJ, et al. Coronary collaterals and myocardial viability in patients with chronic total occlusion[J]. EuroIntervention, 2020, 16(6): e453-e461.
[30] Ybarra LF, Rinfret S, Brilakis ES, et al. Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies: CTO-ARC consensus recommendations[J]. Circulation, 2021, 143(5): 479-500.
Options
文章导航

/

〈 〉